ProQR Therapeutics Announces Board Nomination and AGM

TipRanksApr 23 19:27

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting

ProQR Therapeutics NV (Nasdaq: PRQR) today announced it will present new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.

GlobeNewswireApr 23 04:31

Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx

Yahoo FinanceApr 22 19:51

ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.The opposition was filed in June 2021 with the

BenzingaApr 19 19:06

ProQR Therapeutics Is Maintained at Neutral by Citigroup

ProQR Therapeutics Is Maintained at Neutral by Citigroup

Dow JonesApr 19 00:16

ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup

ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup

Dow JonesApr 19 00:16